CY1120742T1 - Ρυθμιστες του υποδοχεα χ ηπατος (lxr) για τη θεραπεια δερματικων ασθενειων, διαταραχων και καταστασεων - Google Patents
Ρυθμιστες του υποδοχεα χ ηπατος (lxr) για τη θεραπεια δερματικων ασθενειων, διαταραχων και καταστασεωνInfo
- Publication number
- CY1120742T1 CY1120742T1 CY181101037T CY181101037T CY1120742T1 CY 1120742 T1 CY1120742 T1 CY 1120742T1 CY 181101037 T CY181101037 T CY 181101037T CY 181101037 T CY181101037 T CY 181101037T CY 1120742 T1 CY1120742 T1 CY 1120742T1
- Authority
- CY
- Cyprus
- Prior art keywords
- lxr
- disorders
- treatment
- conditions
- skin diseases
- Prior art date
Links
- 208000017520 skin disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000035475 disorder Diseases 0.000 title 1
- 238000004353 relayed correlation spectroscopy Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/16—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261606160P | 2012-03-02 | 2012-03-02 | |
| PCT/US2013/028438 WO2013130892A1 (en) | 2012-03-02 | 2013-02-28 | Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1120742T1 true CY1120742T1 (el) | 2019-12-11 |
Family
ID=49083313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY181101037T CY1120742T1 (el) | 2012-03-02 | 2018-10-08 | Ρυθμιστες του υποδοχεα χ ηπατος (lxr) για τη θεραπεια δερματικων ασθενειων, διαταραχων και καταστασεων |
Country Status (25)
| Country | Link |
|---|---|
| US (5) | US8987318B2 (enExample) |
| EP (2) | EP3441390A1 (enExample) |
| JP (2) | JP6378630B2 (enExample) |
| KR (1) | KR102112879B1 (enExample) |
| CN (1) | CN104284893B (enExample) |
| AU (1) | AU2013225840B2 (enExample) |
| BR (1) | BR112014021515A2 (enExample) |
| CA (1) | CA2866113C (enExample) |
| CY (1) | CY1120742T1 (enExample) |
| DK (1) | DK2820013T3 (enExample) |
| ES (1) | ES2691079T3 (enExample) |
| HR (1) | HRP20181623T1 (enExample) |
| HU (1) | HUE040231T2 (enExample) |
| IL (1) | IL234413B (enExample) |
| LT (1) | LT2820013T (enExample) |
| MX (1) | MX361349B (enExample) |
| NZ (1) | NZ629636A (enExample) |
| PL (1) | PL2820013T3 (enExample) |
| PT (1) | PT2820013T (enExample) |
| RS (1) | RS57863B9 (enExample) |
| SG (2) | SG10201607345YA (enExample) |
| SI (1) | SI2820013T1 (enExample) |
| SM (1) | SMT201800630T1 (enExample) |
| TR (1) | TR201815013T4 (enExample) |
| WO (1) | WO2013130892A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201607345YA (en) | 2012-03-02 | 2016-11-29 | Ralexar Therapeutics Inc | Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions |
| JP6456909B2 (ja) * | 2013-03-15 | 2019-01-23 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｌｘｒ調節因子 |
| CN104151300B (zh) * | 2013-05-15 | 2018-07-13 | 中国医学科学院医药生物技术研究所 | 一组2,3-二取代的苯并喹唑啉类的肝x受体的激动剂及用途 |
| RS60479B1 (sr) | 2013-09-04 | 2020-08-31 | Ellora Therapeutics Inc | Modulatori receptora x jetre (lxr) |
| JP2016532713A (ja) * | 2013-09-04 | 2016-10-20 | アレクサー セラピューティクス， インク． | 肝臓ｘ受容体（ｌｘｒ）調節因子 |
| WO2015106164A1 (en) | 2014-01-10 | 2015-07-16 | Rgenix, Inc. | Lxr agonists and uses thereof |
| US20190365784A1 (en) | 2015-12-30 | 2019-12-05 | Raúl Enrique MASSONE | Use of brassinosteroid analogs for the treatment of dermal disorders by selectively modulating liver x receptors (lxr) and dermal disease treatment by brassinosteroid analogs acting as selective liver x receptor (lxr) modulators |
| EP3402477A4 (en) | 2016-01-11 | 2019-08-21 | The Rockefeller University | METHOD FOR THE TREATMENT OF DISEASES RELATED TO MYELOID-DERIVED SUPPRESSOR CELLS |
| CA3078981A1 (en) | 2017-11-21 | 2019-05-31 | Rgenix, Inc. | Polymorphs and uses thereof |
| EP3999055A1 (en) | 2019-07-15 | 2022-05-25 | Novartis AG | Methods for treating meibomian gland dysfunction with liver x receptor agonists |
| TWI888447B (zh) | 2019-12-13 | 2025-07-01 | 美商因思博納公司 | 金屬鹽及其用途 |
| WO2022249006A1 (en) * | 2021-05-24 | 2022-12-01 | Novartis Ag | Use of 1,2,4-oxadiazole derivatives as liver x receptor agonists |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1199771A (en) * | 1915-07-01 | 1916-10-03 | Bates Valve Bag Co | Wire-twisting machine. |
| WO2002024632A2 (en) | 2000-09-18 | 2002-03-28 | Glaxo Group Limited | Substituted aminopropoxyaryl derivatives useful as agonists for lxr |
| AUPR738301A0 (en) | 2001-08-30 | 2001-09-20 | Starpharma Limited | Chemotherapeutic agents |
| US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
| WO2003099769A1 (en) | 2002-05-24 | 2003-12-04 | Pharmacia Corporation | Anilino liver x-receptor modulators |
| MXPA04011690A (es) | 2002-05-24 | 2005-03-31 | Pharmacia Corp | Moduladores de receptor x de higado de sulfona. |
| WO2004058717A1 (en) | 2002-12-20 | 2004-07-15 | X-Ceptor Therapeutics, Inc. | Isoquinolinone derivatives and their use as therapeutic agents |
| JP2006193426A (ja) | 2003-09-05 | 2006-07-27 | Sankyo Co Ltd | 置換された縮環ピリミジン−４（３ｈ）−オン化合物 |
| WO2005113499A1 (ja) | 2004-05-20 | 2005-12-01 | Sankyo Company, Limited | インドール化合物 |
| TW200606133A (en) | 2004-06-30 | 2006-02-16 | Sankyo Co | Substituted benzene compounds |
| EP1773781A2 (en) | 2004-08-03 | 2007-04-18 | Wyeth | Indazoles useful in treating cardiovascular diseases |
| US20070060589A1 (en) * | 2004-12-21 | 2007-03-15 | Purandare Ashok V | Inhibitors of protein arginine methyl transferases |
| WO2006109633A1 (ja) | 2005-04-07 | 2006-10-19 | Daiichi Sankyo Company, Limited | 置換インドール化合物 |
| US7213797B2 (en) | 2005-05-20 | 2007-05-08 | Garland Jerome Gaskins | Deck board straightener |
| SG162803A1 (en) * | 2005-06-27 | 2010-07-29 | Exelixis Inc | Imidazole based lxr modulators |
| BRPI0612287A8 (pt) * | 2005-06-27 | 2019-01-22 | Exelixis Inc | composição para uso farmacêutico no tratamento de doenças através da medicina nuclear e métodos de uso e para modulação de atividade de receptor nuclear |
| EP1940786B1 (en) | 2005-09-16 | 2010-08-18 | Arrow Therapeutics Limited | Biphenyl derivatives and their use in treating hepatitis c |
| WO2007034279A2 (en) | 2005-09-19 | 2007-03-29 | Pfizer Products Inc. | C3a antagonists and pharmaceutical compositions thereof |
| CN101309915A (zh) | 2005-11-14 | 2008-11-19 | Irm责任有限公司 | 作为lxr调节剂的化合物和组合物 |
| EP1849781A1 (en) | 2006-04-28 | 2007-10-31 | Laboratorios del Dr. Esteve S.A. | Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments |
| TW200825054A (en) | 2006-10-18 | 2008-06-16 | Wyeth Corp | Quinoline compounds |
| KR20090094125A (ko) | 2006-12-08 | 2009-09-03 | 엑셀리시스, 인코포레이티드 | Ｌｘｒ 및 ｆｘｒ 조절자 |
| EP2137158A4 (en) * | 2007-02-28 | 2012-04-18 | Methylgene Inc | LOW-MOLECULAR INHIBITORS OF PROTEINARGININE METHYLTRANSFERASES (PRMTS) |
| EP2142517A2 (en) | 2007-05-18 | 2010-01-13 | Wyeth | Quinazoline compounds |
| WO2009011850A2 (en) * | 2007-07-16 | 2009-01-22 | Abbott Laboratories | Novel therapeutic compounds |
| JP5220858B2 (ja) | 2007-08-13 | 2013-06-26 | エフ．ホフマン−ラ ロシュ アーゲー | 新規ピペラジンアミド誘導体 |
| EP2231660A1 (en) | 2007-12-21 | 2010-09-29 | Wyeth LLC | Imidazo [1,2-a] pyridine compounds |
| JP2011507905A (ja) | 2007-12-21 | 2011-03-10 | ワイス・エルエルシー | ベンズイミダゾール化合物 |
| EP2418207A1 (en) * | 2008-05-13 | 2012-02-15 | Boehringer Ingelheim International GmbH | Sulfone compounds which modulate the CB2 receptor |
| US8063088B2 (en) | 2008-06-11 | 2011-11-22 | Hoffmann-La Roche Inc. | Imidazolidine derivatives |
| US20100120778A1 (en) | 2008-11-07 | 2010-05-13 | Wyeth | Quinoxaline-based lxr modulators |
| EP2367801A1 (en) | 2008-11-19 | 2011-09-28 | Wyeth LLC | Polar quinazolines as liver x receptors ( lxrs ) modulators |
| EP2379563B1 (en) | 2008-12-22 | 2014-07-16 | Merck Sharp & Dohme Corp. | Gamma secretase modulators |
| US20120058133A1 (en) * | 2009-02-19 | 2012-03-08 | President And Fellows Of Harvard College | Inhibition of trna synthetases and therapeutic applications thereof |
| US20120040977A1 (en) | 2009-02-23 | 2012-02-16 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| KR101676704B1 (ko) | 2009-05-28 | 2016-11-16 | 엑셀리시스 페이턴트 컴퍼니 엘엘씨 | Ｌｘｒ 조절자 |
| US20120263646A1 (en) | 2009-10-15 | 2012-10-18 | Guerbet | Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases |
| GB0919757D0 (en) | 2009-11-12 | 2009-12-30 | Johnson Matthey Plc | Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs |
| US8906943B2 (en) | 2010-08-05 | 2014-12-09 | John R. Cashman | Synthetic compounds and methods to decrease nicotine self-administration |
| US20130137865A1 (en) * | 2010-08-11 | 2013-05-30 | Taisho Pharmaceutical Co., Ltd. | Heteroaryl-pyrazole derivative |
| EP2609095A4 (en) * | 2010-08-27 | 2014-06-18 | Calcimedica Inc | COMPOUNDS MODULATING INTRACELLULAR CALCIUM |
| AR088728A1 (es) | 2011-03-25 | 2014-07-02 | Bristol Myers Squibb Co | Moduladores de lxr como prodroga de imidazol |
| SG10201607345YA (en) | 2012-03-02 | 2016-11-29 | Ralexar Therapeutics Inc | Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions |
| AU2013302861A1 (en) | 2012-08-13 | 2015-03-05 | The Rockefeller University | Treatment and diagnosis of melanoma |
| JP2016532713A (ja) | 2013-09-04 | 2016-10-20 | アレクサー セラピューティクス， インク． | 肝臓ｘ受容体（ｌｘｒ）調節因子 |
| RS60479B1 (sr) | 2013-09-04 | 2020-08-31 | Ellora Therapeutics Inc | Modulatori receptora x jetre (lxr) |
-
2013
- 2013-02-28 SG SG10201607345YA patent/SG10201607345YA/en unknown
- 2013-02-28 NZ NZ629636A patent/NZ629636A/en not_active IP Right Cessation
- 2013-02-28 HU HUE13754329A patent/HUE040231T2/hu unknown
- 2013-02-28 BR BR112014021515-4A patent/BR112014021515A2/pt active Search and Examination
- 2013-02-28 HR HRP20181623TT patent/HRP20181623T1/hr unknown
- 2013-02-28 PL PL13754329T patent/PL2820013T3/pl unknown
- 2013-02-28 DK DK13754329.4T patent/DK2820013T3/en active
- 2013-02-28 SI SI201331198T patent/SI2820013T1/sl unknown
- 2013-02-28 SG SG11201405378VA patent/SG11201405378VA/en unknown
- 2013-02-28 SM SM20180630T patent/SMT201800630T1/it unknown
- 2013-02-28 MX MX2014010537A patent/MX361349B/es active IP Right Grant
- 2013-02-28 EP EP18182346.9A patent/EP3441390A1/en not_active Withdrawn
- 2013-02-28 EP EP13754329.4A patent/EP2820013B9/en active Active
- 2013-02-28 ES ES13754329.4T patent/ES2691079T3/es active Active
- 2013-02-28 JP JP2014560060A patent/JP6378630B2/ja not_active Expired - Fee Related
- 2013-02-28 RS RS20181179 patent/RS57863B9/sr unknown
- 2013-02-28 LT LTEP13754329.4T patent/LT2820013T/lt unknown
- 2013-02-28 CA CA2866113A patent/CA2866113C/en not_active Expired - Fee Related
- 2013-02-28 AU AU2013225840A patent/AU2013225840B2/en not_active Ceased
- 2013-02-28 KR KR1020147027825A patent/KR102112879B1/ko not_active Expired - Fee Related
- 2013-02-28 CN CN201380018482.7A patent/CN104284893B/zh not_active Expired - Fee Related
- 2013-02-28 PT PT13754329T patent/PT2820013T/pt unknown
- 2013-02-28 WO PCT/US2013/028438 patent/WO2013130892A1/en not_active Ceased
- 2013-02-28 TR TR2018/15013T patent/TR201815013T4/tr unknown
-
2014
- 2014-09-01 IL IL234413A patent/IL234413B/en active IP Right Grant
- 2014-09-02 US US14/474,490 patent/US8987318B2/en not_active Expired - Fee Related
-
2015
- 2015-02-12 US US14/621,255 patent/US9637481B2/en not_active Expired - Fee Related
-
2017
- 2017-04-03 US US15/477,140 patent/US20170334897A1/en not_active Abandoned
-
2018
- 2018-04-18 US US15/956,389 patent/US20180370959A1/en not_active Abandoned
- 2018-08-02 JP JP2018145589A patent/JP6800922B2/ja not_active Expired - Fee Related
- 2018-10-08 CY CY181101037T patent/CY1120742T1/el unknown
-
2020
- 2020-05-13 US US15/931,403 patent/US20210101895A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1120742T1 (el) | Ρυθμιστες του υποδοχεα χ ηπατος (lxr) για τη θεραπεια δερματικων ασθενειων, διαταραχων και καταστασεων | |
| CY1124407T1 (el) | Ενωσεις αναστολεα αυτοταξινης | |
| CY1124055T1 (el) | Ετεροκυκλικες ενωσεις ως ανοσοδιαμορφωτες | |
| CY1124918T1 (el) | Ρυθμιστες ccr2 | |
| CY1124729T1 (el) | Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου | |
| CY1122984T1 (el) | Καρβαμιδικες ενωσεις και μεθοδοι παρασκευης και χρησης τους | |
| CY1124595T1 (el) | Ρυθμιση δραστικοτητας συμπληρωματος | |
| CY1124059T1 (el) | Αζαβενζιμιδαζολια και χρηση αυτων ως ρυθμιστες υποδοχεα ampa | |
| CY1124436T1 (el) | Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια | |
| CY1121989T1 (el) | Φαρμακοτεχνικες μορφες αντισωματων | |
| CY1121170T1 (el) | Νεες ενωσεις ως ρυθμιστες πρωτεϊνικων κινασων | |
| CY1121413T1 (el) | Διυδροπυρρολοπυριδινης αναστολεις ror-γαμμα | |
| CY1118379T1 (el) | Αναστολεις ιου ηπατιτιδας c | |
| CY1117745T1 (el) | Ετεροκυκλικες ενωσεις και χρηση αυτων ως ρυθμιστες υποδοχεα τυπου iii κινασων τυροσινης | |
| JO3474B1 (ar) | مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1 | |
| MX2017013562A (es) | Reguladores de microbioma y usos relacionados de los mismos. | |
| DOP2016000295A (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7 | |
| UY34542A (es) | ?formulaciones farmacéuticas para conjugados de derivados de fumagilina y phf?. | |
| MX387596B (es) | Degradadores selectivos del receptor de estrógeno y sus usos. | |
| CL2016002072A1 (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| GT201500069A (es) | Piridinonas bicìclicas novedosas | |
| CL2016002091A1 (es) | Compuesto de triazina y su uso para fines medicinales | |
| CO6771450A2 (es) | Ureas asimétricas y usos médicos de las mismas | |
| CY1121326T1 (el) | Υποκατεστημενη 2,4 διαμινο-κινολινη ως νεοι αντικαρκινικοι παραγοντες | |
| MX377304B (es) | Derivados de piperazina como moduladores de los receptores x del hígado. |